Glaukos (NYSE:GKOS) Price Target Raised to $145.00

Glaukos (NYSE:GKOS) had its target price hoisted by equities researchers at Wells Fargo & Company from $135.00 to $145.00 in a research note issued on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price target would indicate a potential upside of 15.07% from the company’s current price.

Several other equities analysts have also recently weighed in on the stock. StockNews.com raised shares of Glaukos from a “sell” rating to a “hold” rating in a research note on Monday, October 21st. BTIG Research raised their target price on shares of Glaukos from $131.00 to $139.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. Morgan Stanley lifted their target price on Glaukos from $100.00 to $120.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Stifel Nicolaus increased their price target on Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, Citigroup cut shares of Glaukos from a “buy” rating to a “neutral” rating and raised their target price for the company from $130.00 to $132.00 in a research note on Wednesday, July 10th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, Glaukos presently has an average rating of “Moderate Buy” and a consensus target price of $131.36.

Glaukos Stock Down 4.1 %

NYSE GKOS traded down $5.37 on Tuesday, reaching $126.01. The company had a trading volume of 608,135 shares, compared to its average volume of 571,039. The company’s fifty day moving average is $129.64 and its 200-day moving average is $119.98. The firm has a market capitalization of $6.92 billion, a price-to-earnings ratio of -38.76 and a beta of 1.02. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.67 and a current ratio of 5.48. Glaukos has a 1-year low of $59.22 and a 1-year high of $139.51.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20. The company had revenue of $96.70 million for the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. The company’s quarterly revenue was up 23.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.50) earnings per share. On average, research analysts forecast that Glaukos will post -2.16 earnings per share for the current fiscal year.

Insider Transactions at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 2,275 shares of the stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total value of $316,156.75. Following the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at $14,198,425.93. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Glaukos news, Director Marc Stapley sold 6,250 shares of Glaukos stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $125.93, for a total value of $787,062.50. Following the completion of the sale, the director now owns 34,076 shares in the company, valued at $4,291,190.68. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Joseph E. Gilliam sold 2,275 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the completion of the sale, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at $14,198,425.93. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 41,525 shares of company stock worth $5,142,029. 6.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Glaukos

Several institutional investors have recently made changes to their positions in the stock. Values First Advisors Inc. bought a new stake in shares of Glaukos during the 3rd quarter valued at $25,000. GAMMA Investing LLC grew its stake in Glaukos by 68.8% during the second quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock worth $141,000 after buying an additional 486 shares in the last quarter. Fifth Third Wealth Advisors LLC bought a new position in Glaukos in the 2nd quarter valued at about $187,000. Brighton Jones LLC bought a new position in Glaukos in the 2nd quarter valued at about $208,000. Finally, Procyon Advisors LLC acquired a new position in shares of Glaukos in the 3rd quarter valued at approximately $210,000. 99.04% of the stock is currently owned by institutional investors.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.